We previously demonstrated that constitutively active AHR in breast cancer lines preferentially drives Cyp1b1 expression while an exogenous ligand, e.g. DMBA, tends to induce greater fold-increases in Cyp1a1 than Cyp1b1 [15]. The gene discussed is CYP1A1; the disease is breast cancer.